论文部分内容阅读
国外文献中所记载的重型再生障碍性贫血(简称重再),包括我国分类中急性再障与部分重型慢性再障。采用常规疗法(同化激素、输血、皮质激素、抗生素等)治疗重再,患者长期生存率仅25％,且雄激素对重再无效。现在,国外将骨髓移植(BMT)作为治疗重再的主要手段。10余年来,BMT治疗重再的疗效不断捉高,使有输血史的患者长期生存率从1976年的41％升至1982年的70％;无输血史的患者生存率已达到82％。现将提高BMT治疗重再的存活率的有关问题作一介绍。
Heavy aplastic anemia (referred to as repeated again) recorded in foreign literature, including our country classification of acute aplastic anemia and partial heavy chronic aplastic anemia. With conventional therapy (anabolic hormone, transfusion, corticosteroids, antibiotics, etc.) treatment again and again, the long-term survival rate of patients was only 25%, and androgen again and again invalid. Now, foreign bone marrow transplantation (BMT) as the main means of treatment again. For more than 10 years, the repeated curative effect of BMT treatment has been continuously raised. The long-term survival rate of patients with history of blood transfusion rose from 41% in 1976 to 70% in 1982; the survival rate of patients without blood transfusion reached 82%. Now to improve the treatment of BMT re-survival rate of the related issues to make an introduction.